Tenderwize
Back to tender search

Non-exclusive pharmaceutical rebate agreement for Formoterol/Aclidiniumbromide

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Jun 30, 2027 · 265 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Formoterol/Aclidiniumbromid (ATC-Code nach WHO: R03AL05)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

No guaranteed minimum purchase volume; quantities depend on patient numbers, prescription behavior, and pharmacy stocki...

The buyer may end the Open-House procedure prematurely if exclusive agreements are concluded, which typically occurs 8-...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Jun 30, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Conclusion of non-exclusive rebate agreements according to §130a Abs. 8 SGB V for the active ingredient Formoterol/Aclidiniumbromide (ATC R03AL05).
  • Open-House model: no individual negotiations, no exclusivity, continuous acceptance of participation requests.
Show full summary

Non-exclusive pharmaceutical rebate agreement (Open-House model) for the active ingredient Formoterol/Aclidiniumbromide (ATC R03AL05) under §130a Abs. 8 SGB V. The agreement is open to all qualified pharmaceutical companies throughout the participation period. No exclusivity, no guaranteed minimum volumes, and the contract ends by 30 June 2027 regardless of conclusion date. The buyer (AOK PLUS) reserves the right to terminate the procedure early if exclusive agreements are signed.

Risks

No guaranteed minimum purchase volume; quantities depend on patient numbers, prescription behavior, and pharmacy stocki...

The buyer may end the Open-House procedure prematurely if exclusive agreements are concluded, which typically occurs 8-...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered medicines.

Eligibility

  • Declaration of no exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen).

Administrative

  • Submission of participation documents via DTVP portal (access request required).

Requirements may be incomplete.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive pharmaceutical rebate agreement for Formoterol/Aclidiniumbromide

Open-House model for concluding non-exclusive rebate agreements for the active ingredient Formoterol/Aclidiniumbromide (ATC R03AL05). Any pharmaceutical company meeting participation conditions may join. No exclusivity, unknown purchase quantities, no minimum volume guarantee. Contract valid until 30 June 2027.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jun 2026 - Jun 2027

Category

Pharmaceutical products

Deadline

Deadline Jun 30, 2027

Procurement Details

Publication date
05 May 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
309969-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30